These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 9034684)

  • 21. Skincare products containing low concentrations of formaldehyde detected by the chromotropic acid method cannot be safely used in formaldehyde-allergic patients.
    Hauksson I; Pontén A; Gruvberger B; Isaksson M; Engfeldt M; Bruze M
    Br J Dermatol; 2016 Feb; 174(2):371-9. PubMed ID: 26480304
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is quaternium-15 a formaldehyde releaser? Correlation between positive patch test reactions to formaldehyde and quaternium-15.
    Odhav A; Belsito DV
    Dermatitis; 2012; 23(1):39-43. PubMed ID: 22653068
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allergic reactivity for different dilutions of eugenol in repeated open application test and patch testing.
    Ofenloch RF; Andersen KE; Foti C; Giménez-Arnau AM; Mowitz M; Salvador JFS; Svedman C; Bruze M
    Contact Dermatitis; 2023 Aug; 89(2):95-102. PubMed ID: 37218587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Repeated open application tests with methyldibromoglutaronitrile in dermatitis patients with and without hypersensitivity to methyldibromoglutaronitrile.
    Isaksson M; Gruvberger B; Bruze M
    Dermatitis; 2007 Dec; 18(4):203-7. PubMed ID: 18021599
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is a specific eyelid patch test series useful? Results of a French prospective study.
    Assier H; Tetart F; Avenel-Audran M; Barbaud A; Ferrier-le Bouëdec MC; Giordano-Labadie F; Milpied B; Amsler E; Collet E; Girardin P; Soria A; Waton J; Truchetet F; Bourrain JL; Gener G; Bernier C; Raison-Peyron N;
    Contact Dermatitis; 2018 Sep; 79(3):157-161. PubMed ID: 29882592
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The time-dose-response relationship for elicitation of contact dermatitis in isoeugenol allergic individuals.
    Andersen KE; Johansen JD; Bruze M; Frosch PJ; Goossens A; Lepoittevin JP; Rastogi S; White I; Menné T
    Toxicol Appl Pharmacol; 2001 Feb; 170(3):166-71. PubMed ID: 11162781
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical relevance of positive patch test reactions to lanolin: A ROAT study.
    Uldahl A; Engfeldt M; Svedman C
    Contact Dermatitis; 2021 Jan; 84(1):41-49. PubMed ID: 32844454
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Formaldehyde-releasers in cosmetics: relationship to formaldehyde contact allergy. Part 1. Characterization, frequency and relevance of sensitization, and frequency of use in cosmetics.
    de Groot AC; White IR; Flyvholm MA; Lensen G; Coenraads PJ
    Contact Dermatitis; 2010 Jan; 62(1):2-17. PubMed ID: 20136875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patch Testing With Formaldehyde 2.0% (0.60 mg/cm2) Detects More Contact Allergy to Formaldehyde Than 1.0.
    Isaksson M; Ale I; Andersen KE; Goh CL; Goossens A; Jerajani H; Matsunaga K; McFadden J; Bruze M
    Dermatitis; 2019; 30(6):342-346. PubMed ID: 31730552
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Results of patch testing to personal care product allergens in a standard series and a supplemental cosmetic series: an analysis of 945 patients from the Mayo Clinic Contact Dermatitis Group, 2000-2007.
    Wetter DA; Yiannias JA; Prakash AV; Davis MD; Farmer SA; el-Azhary RA
    J Am Acad Dermatol; 2010 Nov; 63(5):789-98. PubMed ID: 20643495
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patch testing with 2.0% (0.60 mg/cm 2) formaldehyde instead of 1.0% (0.30 mg/cm 2) detects significantly more contact allergy.
    Pontén A; Aalto-Korte K; Agner T; Andersen KE; Giménez-Arnau AM; Gonçalo M; Goossens A; Johansen JD; Le Coz CJ; Maibach HI; Rustemeyer T; White IR; Bruze M
    Contact Dermatitis; 2013 Jan; 68(1):50-3. PubMed ID: 23035891
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitative patch and repeated open application testing in hydroxyisohexyl 3-cyclohexene carboxaldehyde sensitive-patients.
    Schnuch A; Uter W; Dickel H; Szliska C; Schliemann S; Eben R; Ruëff F; Gimenez-Arnau A; Löffler H; Aberer W; Frambach Y; Worm M; Niebuhr M; Hillen U; Martin V; Jappe U; Frosch PJ; Mahler V
    Contact Dermatitis; 2009 Sep; 61(3):152-62. PubMed ID: 19780773
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ten-year trends in contact allergy to formaldehyde and formaldehyde-releasers.
    Fasth IM; Ulrich NH; Johansen JD
    Contact Dermatitis; 2018 Nov; 79(5):263-269. PubMed ID: 30079600
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Provocative use tests in CAPB-allergic subjects with CAPB-containing product.
    Fartasch M; Diepgen TL; Kuhn M; Basketter DA
    Contact Dermatitis; 1999 Jul; 41(1):30-4. PubMed ID: 10416705
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patch test reactivity to DMDM hydantoin. Relationship to formaldehyde allergy.
    de Groot AC; van Joost T; Bos JD; van der Meeren HL; Weyland JW
    Contact Dermatitis; 1988 Apr; 18(4):197-201. PubMed ID: 3378426
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Positive patch test reactions to formaldehyde releasers indicating contact allergy to formaldehyde.
    Geier J; Lessmann H; Hellriegel S; Fuchs T
    Contact Dermatitis; 2008 Mar; 58(3):175-7. PubMed ID: 18279163
    [No Abstract]   [Full Text] [Related]  

  • 37. Relevance and avoidance of skin-care product allergens: pearls and pitfalls.
    Nelson SA; Yiannias JA
    Dermatol Clin; 2009 Jul; 27(3):329-36, vii. PubMed ID: 19580927
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The repeated open application test (ROAT).
    Hannuksela M; Salo H
    Contact Dermatitis; 1986 Apr; 14(4):221-7. PubMed ID: 2941220
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What is the optimal duration for a ROAT? The experience of the French Dermatology and Allergology group (DAG).
    Amsler E; Assier H; Soria A; Bara C; Ferrier le Bouëdec MC; Barbaud A; Milpied B; Giordano-Labadie F; Pasteur J; Badaoui A; Valois A; Castelain F; Kurihara F; Castagna J; Boulard C; Bernier C; Leleu C; Marcant P; Crépy MN; Tetart F; Raison-Peyron N;
    Contact Dermatitis; 2022 Aug; 87(2):170-175. PubMed ID: 35383393
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Routine diagnostic patch-testing with formaldehyde 2.0% (0.6 mg/cm2) may be an advantage compared to 1.0%.
    Hauksson I; Pontén A; Gruvberger B; Isaksson M; Bruze M
    Acta Derm Venereol; 2010 Sep; 90(5):480-4. PubMed ID: 20814622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.